

10/531036

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				IC13 Complete if Known <b>12 APR 2009</b>	
				Application Number	New Application
				Filing Date	Herewith
				First Named Inventor	Karsten EULENBERG et al
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	1	of	2	Attorney Docket Number	2923-696

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
not considered		WO	99/23216	A	Univ Arizona	5/14/99	
↓	2.	WO	02/079238	A	Eulenberg et al	10/10/02	
	3.	WO	03/050296	A	Aventis Pharma GmbH	6/19/03	
Examiner Signature	/Anoop Singh/				Date Considered	09/19/2007	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

10/531036

Complete if Known  
JC13 REC-6 PCT/PTO 12 APR 2005

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	New Application
Filing Date	Herewith
First Named Inventor	Karsten EULENBERG et al
Group Art Unit	
Examiner Name	
Confirmation No.	
Attorney Docket Number	2923-696

Sheet

2

of

2

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	4.	DATABASE EMBL [Online] 9 January 2002, "Sequence 7735 from Patent W00194629", Database accession no. AX337226 abstracts & WO/01/94629A 13 December 2001.	
not considered no copy is provided	5.	Ike et al, "Structure and promoter activity of the gene encoding ornithine decarboxylase antizyme expressed exclusively in haploid germ cells in testis (OAZ1/Oaz3)", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, vol. 298, no. 2, 2 October 2002, pgs. 183-193.	
	6.	Hayashi et al., "Ornithine decarboxylase antizyme: a novel type of regulatory protein", TIBS TRENDS IN BIOCHEMICAL SCIENCES, vol. 21, no. 1, 1996, pgs. 27-30.	
	7.	Zhou et al., "Structure of human ornithine decarboxylase antizyme 2 gene", GENE, vol. 232, no. 2, 31 May 1999, pgs. 165-171.	
Examiner Signature	/Anoop Singh/	Date Considered	09/19/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.